Back to videosA look into the state of the joint replacement segment as we move into 2026, including emerging share opportunities for challengers like Enovis and Medacta, the battle for technology leadership and the impact of active portfolio management. Mike Evers is an analyst and writer with over 15 years of...
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
